MSC Exosomes for Diabetic Wound Care
Diabetic and chronic wounds are a major focus of MSC-derived exosome research. This overview is for research and educational purposes only.
What MSC exosomes are
MSC-derived exosomes are nanoscale, cell-free extracellular vesicles carrying signaling cargo such as proteins, lipids, and microRNA. BioRegenEx supplies characterized, research-use-only material with per-lot documentation.
What the research explores
In preclinical diabetic-wound and chronic-wound models, MSC-derived exosomes have been studied for signaling related to angiogenesis, inflammation, and tissue repair. These are research findings only. The studies are indexed in our Exosome Research Library under Skin, Wound & Hair and Metabolic & Diabetic.
Sourcing considerations
Look for characterized lots, sterility and endotoxin screening, cold-chain handling, and clear research-use-only labeling. See our overview of MSC exosomes for wound healing.
Frequently Asked Questions
Are MSC exosomes an approved treatment for diabetic wounds?
No. They are not FDA-approved to treat diabetic wounds or any condition and are supplied for research use only (RUO).
What does the wound research focus on?
Preclinical research focuses on angiogenesis, inflammation, and tissue-repair signaling in wound models.
For research and educational purposes; research-use-only.
These statements have not been evaluated by the FDA. BioRegenEx supplies MSC-derived exosomes for research use only (RUO); they are not intended to diagnose, treat, cure, or prevent any disease. This content is educational and is not medical advice.
